Clovis Oncology (NASDAQ: CLVS)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-03 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.430 | -0.440 | -0.0100 | ||||
REV | 36.970M | 34.247M | -2.723M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Clovis Oncology (NASDAQ: CLVS) through any online brokerage.
Other companies in Clovis Oncology’s space includes: Anixa Biosciences (NASDAQ:ANIX), CytomX Therapeutics (NASDAQ:CTMX), Humanigen (NASDAQ:HGEN), Finch Therapeutics Group (NASDAQ:FNCH) and Nymox Pharmaceutical (NASDAQ:NYMX).
The latest price target for Clovis Oncology (NASDAQ: CLVS) was reported by HC Wainwright & Co. on Friday, May 6, 2022. The analyst firm set a price target for 0.00 expecting CLVS to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
The stock price for Clovis Oncology (NASDAQ: CLVS) is $0.8462 last updated Today at May 16, 2022, 6:32 PM UTC.
There are no upcoming dividends for Clovis Oncology.
Clovis Oncology’s Q2 earnings are confirmed for Wednesday, August 3, 2022.
There is no upcoming split for Clovis Oncology.
Clovis Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.